Insights

Professional
Practice
Industry
Region
Trending Topics
Location
Type

Sort by:

Client Alerts 6331 results

Client Alert | 7 min read | 10.22.26

Africa, MENA, and the Arbitration Act 2025: LCIA’s Latest Report

The LCIA's 2025 Annual Casework Report contains a finding that should command the attention of any business with commercial exposure to Africa or the Middle East. Participation from the Middle East and North Africa (MENA) rose to almost 15% of the LCIA's caseload in 2025, and the UAE alone is now the third most represented jurisdiction globally, overtaking every non-Anglophone jurisdiction in the world.[1] That shift did not happen in isolation. It coincided with the entry into force of the Arbitration Act 2025 (the 2025 Act) — the most significant reform of English arbitration law in a generation — and a dramatic surge in parties deploying the LCIA's procedural toolkit more aggressively than ever before.[2]
...

Client Alert | 4 min read | 10.22.26

CMS Proposal Would Require Extensive Provider Directory Changes in MA

A proposed rule published October 20, 2026, outlines a framework that would require Medicare Advantage (MA) plans to verify and update their provider directories at least once every 90 days, report an accuracy score to the Centers for Medicare and Medicaid Servies (CMS), and publicly post it on their directories. CMS says the proposed changes will improve data connectivity and accuracy in provider directories across the health care system. 
...

Client Alert | 5 min read | 10.22.26

CMS Proposes Major Changes to MA, Part D, and PBM Requirements

On October 16, 2026, the U.S. Centers for Medicare and Medicaid Services (CMS) issued a proposed rule implementing key sections of the Consolidated Appropriations Act (CAA) of 2026, Section 6224 (“Modernizing and Ensuring Pharmacy Benefit Manager Accountability”). The agency also proposes a conforming change mandated by section 6219 of the CAA (“Adjustments to Medicare Part D Cost-Sharing Reductions for Low-Income Individuals”) that would reduce the generic-drug copayment from $1 to $0 for full-benefit dual eligible individuals. Comments to the proposed rule are due December 15, 2026.   
...

Client Alert | 5 min read | 10.22.26

Some Harm Is Enough: Court Denies Motion to Dismiss EEOC Title VII Claim Over Employer-Sponsored Women-Only Event

On October 16, 2026, the United States District Court for the District of New Hampshire denied Coca-Cola Beverages Northeast, Inc.’s motion to dismiss the U.S. Equal Opportunity Employment Commission’s (EEOC) Title VII sex discrimination lawsuit arising from a women-only company-sponsored event. The Court held that the EEOC had “plausibly met” the applicable legal standard “by pointing to missed networking opportunities, the potential deprivation of paid time off, and the denial of perks including a company-paid hotel stay, food, and beverages.” This ruling is a clear sign that employer-sponsored events limited to employees of one sex carry legal risk, even when the employer’s intent is to address workforce imbalances or attendance at the event does not lead to measurable advantages. 
...

Client Alert | 4 min read | 10.22.26

When the Clock Strikes Twice: Crocs Takes Piecemeal ITC Appeals to the Supreme Court

Crocs, Inc. recently filed a petition for a writ of certiorari before the U.S. Supreme Court (No. 26-421), asking the Court to review and resolve the question: “Whether an agency disposition is final as to some issues, thus triggering deadlines for judicial review, while other issues decided in the same disposition remain subject to further executive or administrative review.”
...

Client Alert | 9 min read | 10.21.26

Artificial Intelligence in Life Sciences: Reliability of AI-Generated Evidence in Drug Discovery and Development

The life sciences sector is uniquely vulnerable to the inherent risks of AI-generated evidence in drug development and discovery. This client alert focuses on five core challenges: hallucinations, skewed predictions from unrepresentative training data, the opacity of AI reasoning, input sensitivity that undermines reproducibility, and adversarial manipulation of training data. To address these risks, companies should use experimental validation and human oversight as the common legal and regulatory safety net. This entails among other measures auditing AI outputs, characterizing training data, and structural oversight. Companies also should prepare for evolving frameworks and guidance from the U.S. Food and Drug Administration (FDA) and the European Union (EU) that address use of AI in drug discovery and development .  
...

Client Alert | 2 min read | 10.21.26

FASCSA Orders Require Exclusion and Removal of DeepSeek AI

New Federal Acquisition Supply Chain Security Act (FASCSA) orders from the Department of Homeland Security (DHS), the Department of War (DoW), and the Director of National Intelligence (DNI) require the exclusion and removal of products and services by DeepSeek and its affiliated entities (collectively, DeepSeek).1 The DoW and DNI orders are laid out in their entirety within the SAM.gov downloadable spreadsheet of FASCSA orders, and neither provides details about the reasons for excluding or removing DeepSeek. By contrast, the civilian order, published on October 20, 2026, identifies DeepSeek’s free open-source artificial intelligence (AI) models as “present[ing] multiple threat vectors.” These include threat vectors associated with the company’s known technical vulnerabilities, obligation to provide the government of the People’s Republic of China certain access, and the fact that information collected by the company’s apps and AI models could be used to create “actionable intelligence” about the U.S. government.   
...

Client Alert | 3 min read | 10.21.26

Private Investigations Act Series: Temporal, material and territorial scope

The Private Investigations Act (PIA), which entered into force on December 16, 2024, fundamentally modernized the framework for private investigation activities in Belgium. Its implications for businesses conducting internal investigations are far-reaching.  
...

Client Alert | 7 min read | 10.21.26

Securities Law for Entrepreneurs

Do you want your startup to expand and become a major player in your industry? If so, you will most likely need to seek capital from outside investors to help you build infrastructure and fulfill orders.
...

Client Alert | 4 min read | 10.20.26

California Follows New York’s Lead in Requiring AI “Synthetic Performer” Disclosures in Advertising

On September 16, 2026, California became the second state in the country to require disclosures of AI-generated synthetic performers in advertising. Governor Gavin Newsom signed into law SB 1050 — a measure that prohibits advertisers from publishing advertisements prominently featuring AI-generated synthetic performers without a clear and conspicuous disclosure — effective January 1, 2027.
...

Client Alert | 5 min read | 10.20.26

What Do Beer, Wine, and T-shirts Have in Common? Lessons from the FTC’s Recent Price Discrimination Cases

There were two significant developments recently at the Federal Trade Commission (FTC) in its enforcement of the Robinson-Patman Act (RPA), a statute that broadly prohibits sellers from engaging in price discrimination that harms competition. First, the Commission settled a litigation against Southern Glazer’s that was initially brought during the Biden administration, and second, the Commission also announced the resolution of an investigation into price discrimination by Gildan Activewear and S&S holdings in the wholesale T-shirt distribution industry. These developments signal a more measured approach to the RPA than in the prior administration but are nonetheless a reminder to companies that the RPA is alive and well and remains an important tool for enforcers and plaintiffs to address price discrimination. Companies that sell to retailers or operate in distribution channels should consider periodic reviews of their pricing structures and compliance programs to ensure compliance with the RPA. 
...

Client Alert | 5 min read | 10.19.26

To Fine or Not to Fine: EDPB Confirms Default Position in GDPR Enforcement Should Be to Fine

On 17 September 2026, the European Data Protection Board (“EDPB”) published its draft Guidelines 04/2026 on the imposition of administrative fines (the "Guidelines"), currently out for public consultation until 13 November 2026. In 2022, the EDPB had adopted guidelines on calculating the amount of an administrative fine (the “Calculation Guidelines”). The present Guidelines fill a gap the Calculation Guidelines left open: they provide a structured, five-step methodology for deciding when to impose a fine and explain how fines interact with the full range of corrective powers. By issuing both sets of guidelines, the EDPB aims to increase harmonization in fining posture. 
...

Client Alert | 6 min read | 10.16.26

Proposed AI Governance Framework: Risk-Mitigation Recommendations for Health Plans

Senator Maria Cantwell (D-Wash), the ranking member of the Senate Committee on Commerce, Science, and Transportation, recently outlined a comprehensive artificial intelligence (AI) governance framework designed to drive legislative and executive actions. The framework is built on six principles and is being introduced at a time when federal AI legislation is actively being debated. While the framework is a proposal, it reflects priorities that have bipartisan resonance and signals where lawmakers are likely to focus. For health insurance payors, several elements of the framework are directly relevant to existing and planned AI deployments, particularly in utilization management, claims processing, and member-facing services.
...

Client Alert | 3 min read | 10.16.26

Sedona Finalizes DTSA Model Jury Instructions: Key Changes from the Draft

The Sedona Conference has published its Defend Trade Secrets Act Model Jury Instructions: DTSA 10th Anniversary Commemorative Edition, the product of Working Group 12’s consensus process. Earlier this year, we alerted clients to the draft instructions. The final publication cautions that the instructions are a starting point only, not binding law, and must be tailored to the facts, claims, and governing law of each case. 
...

Client Alert | 3 min read | 10.16.26

USPTO Issues Precedential Decision Expanding Obviousness-Type Double Patenting

Following the Board’s November 8, 2024, decision reversing the Examiner’s OTDP rejections of claims 1-18 of U.S. Application No. 17/135,529 (the ’529 Application), the patent application at issue in Ex parte Baurin, the Examiner filed a request for rehearing. On March 5, 2026, USPTO Director Squires convened the ARP and granted sua sponte rehearing. Eleven amicus briefs were entered into the record on April 1, 2026. 
...

Client Alert | 3 min read | 10.15.26

UK FCA Abandons Mandatory Climate Reporting for Listed Companies in Favour of Comply-or-Explain Regime, But Expands Scope of Covered Entities

The FCA has recently published Policy Statement PS26/19, finalising its rules on sustainability disclosures for listed companies. As discussed in our earlier article here, the FCA had consulted on proposals to replace the existing TCFD-aligned disclosure regime with new requirements based on the UK Sustainability Reporting Standards (UK SRS). The final rules depart from the consultation proposals in a number of significant respects. 
...

Client Alert | 4 min read | 10.14.26

Misleading Privacy Claims Can Trigger Massive Consumer-Protection Liability

At a glance: A New Mexico jury found Meta liable for nearly 44 million deceptive trade practice violations based on misleading privacy and platform-safety statements—showing that public-facing privacy claims can create significant consumer-protection exposure.
...

Client Alert | 5 min read | 10.13.26

New York-Presbyterian Hospital Ruling Signals Widening Antitrust Exposure for Hospital Contracting Practices

On October 1, 2026, Judge Brian M. Cogan of the U.S. District Court for the Eastern District of New York denied NYP’s motion to dismiss a consolidated antitrust complaint brought by three self-funded union health plans. The ruling is significant for two reasons. First, it demonstrates that plaintiffs can successfully allege market power against hospital systems even in the absence of traditionally high market shares. Second, the court’s reasoning closely tracks the arguments advanced by the DOJ in its Statement of Interest filed in the case: that market power need not be established through market share alone and can be shown through direct evidence such as supracompetitive pricing, and that exclusionary conduct and rival foreclosure are not required elements of a Section 1 claim. The recent decision validates the government’s legal theories and could enhance the viability of the DOJ’s parallel action against NYP, which is currently proceeding in the Southern District of New York.
...

Client Alert | 4 min read | 10.08.26

California Governor Signs SB 690, Limiting Private Right of Action Under CIPA’s “Pen Register” and “Trap and Trace” Provisions

At a glance: Governor Gavin Newsom signed SB 690, amending CIPA to restrict private plaintiffs from bringing “pen register” and “trap and trace” claims arising from web-based conduct. The amendment is meant to reduce the wave of private CIPA litigation targeting website tracking technology. However, businesses remain exposed to several major types of claims and enforcement mechanisms under CIPA and related statutes and should audit their tracking technologies, consent mechanisms, and litigation posture accordingly.
...

Client Alert | 4 min read | 10.08.26

Court of Federal Claims Provides a Roadmap for Adequate Rule-of-Two Set Aside Market Research

The Rule of Two is a vital mechanism for ensuring that contracting officers satisfy the federal government’s statutory requirement that 23% of U.S. prime contracts be issued to small businesses. FAR 19.502-2(b) (19.104-1(a) of the RFO) requires that agencies set aside procurements for small businesses when there is a reasonable expectation that at least two responsible small businesses will submit offers at fair market prices.  
...